Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - IMMUNOMEDICS INC | a16-22958_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 12, 2016
Immunomedics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
000-12104 |
|
61-1009366 |
|
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
300 The American Road, Morris Plains, New Jersey |
|
07950 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
(973) 605-8200
(Registrant’s telephone number,
including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Item 7.01. Regulation FD Disclosure.
Immunomedics, Inc. (the “Company”) published an investor presentation, which will be available on the Company’s website, www.immunomedics.com, and is included as Exhibit 99.1 to this report and incorporated herein by reference. The Company is not undertaking to update this presentation. This report should not be deemed an admission as to the materiality of any information contained in the investor presentation.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
|
Description of Exhibit |
|
99.1 |
|
Investor Presentation of Immunomedics, Inc., dated December 2016. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
IMMUNOMEDICS, INC. | ||
|
|
| ||
|
|
By: |
/s/ Michael R. Garone | |
|
|
|
Name: |
Michael R. Garone |
|
|
|
Title: |
Vice President, Finance and Chief Financial Officer |
|
|
|
|
|
|
Date: December 12, 2016 |
|
| |